Novo Nordisk Exceeds Q3 Earnings and Revenue Estimates, Updates 2026 Outlook
Novo Nordisk reported third-quarter financial results that surpassed analyst expectations on both the top and bottom lines. The company posted a non-GAAP earnings per share of DKK 5.79, exceeding estimates by DKK 1.17, while revenue reached DKK 79.19 billion, representing a 6% year-over-year increase and beating projections by DKK 5.79 billion. Looking ahead, the pharmaceutical giant provided updated guidance for its long-term growth trajectory. The company now expects adjusted sales growth for 2026 to range between -2% and +2% at constant exchange rates (CER), alongside updates regarding its adjusted operating profit expectations.
Tickers: $NVO